Clinical value of CA15.3 in breast cancer;Apport du CA15.3 en cancerologie mammaire

Immuno-Analyse et Biologie Specialisee

Volumn 13, Issue 1, 1998, Pages 19-25

  Boccara, C ^a   Basuyau, J P ^a   Brunelle, P ^a   Bastit, P ^a   Berry, M ^a   Chevrier, A ^a   Chinet, P ^a   Graic Y ^a   Julien, J P ^a   Veyret, C ^a  

^a CENTRE HENRI BECQUEREL   (France)

Author keywords

Breast cancer; CA15.3; Prognostic factors; Tumor markers

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0031777613     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2532(97)82730-5     Document Type: Article

References (34)

1. 1 Al Jarallab MA, Behbehani AE, El Nass SA, Temim L, Ebraheem AK, Ali MAA et al. Serum CA 15-3 and CEA patterns in postsurgical follow-up and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993 ; 19 : 74-9
2. 2 Basuyau JP, Brunelle P, Charrot P, Chevallier B, Delapierre F, Graïc Y et al. CA15.3 et diagnostic précoce de récidive dans les cancers du sein. Bull Cancer 1993 ; 80 : 213-8
3. 3 Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NC et al. Tumor markers in patients with advanced breast cancer as prognostic indicators: a preliminary study. Breast Cancer Res Treat 1994 ; 30 : 293-7
4. 4 Blijlevens NM, Oosterhuis WP, Oosten HR, Mulder NH. Clinical value of TPS, CEA and CA15.3 in breast cancer patients. Anticancer Res 1995 ; 15 : 2711-6
5. 5 Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L et al. CA 15-3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 1992 ; 29A Suppl 1 : 144-6
6. 6 Chevallier B, Heintzmann F, Mosseri V, Dauce JP, Bastit P, Graic Y et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis. Cancer 1988 ; 62 : 2517-24
7. 7 Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989 ; 13 : 123-33
8. 8 Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989 ; 64 : 1674-81
9. 9 Coveney EC, Geraghty JG, Sherry F, McDerrnott EW, Fenelly JJ, O'Higgins NJ et al. The clinical value of CEA and CA15.3 in breast cancer management. Int J Biol Markers 1995 ; 10 : 35-41
10. 10 Dixon AR, Jackson L, Chan SY, Badley RA, Blamey RW. Continous chemotherapy in responsive metastaric breast cancer: a role for tumor markers? Br J Cancer 1993 ; 68 : 181-5
11. 11 Ferrero JM, Namer M. Intérêt clinique du CA 15-3 dans le cancer du sein. Immunoanal Biol Spéc 1994 ; 9 : 43-6
12. 12 Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G. Evaluation of CA15-3 serum levels in breast cancer patients. J Nucl Med Allied Sci 1986 ; 30 : 29-36
13. 13 Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A et al. The tumour associated antigen CA 15-3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 1991 ; 63 : 809-13
14. 14 Hilkens J, Kroenzen V, Bonfrer JMG, Bruning PF, Hilghers J, VanEijkeren A. A sandwich radioimmunoassay for a new antigen (MAM-6) present in the sera of patients with metastazied carcinomas. In: Peeters H, ed. Protides of the Biological Fluids. Oxford: Pergamon Press; 1984. p 651-3
15. 15 Horobin JM, Browning MCK, Mc Farlane NP, Smith G, Prece PE, Wood RAB et al. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. J R Coll Surg Edinb 1991 ; 36: 219-21.
16. 16 Jäger W, Merkle E, Lang N. Erlangen tumor marker study on breast cancer. J Tumor Marker Oncol 1991 ; 6 : 56
17. 17 Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Kiovula T. Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988 ; 58 : 213-5
18. 18 Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother pharmacol 1994 ; 35 : 80-3
19. 19 Kufe D, Inghirami G, Abe M, Hayes P, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984 : 3 : 223
20. 20 Martoni A, Zamagni C, Bellanova B, Zanichelli L, Vecchi F, Cacciari N et al. CEA, MCA, CA15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer 1995 ; 31A : 1615-21
21. 21 Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M et al. Use of serial CEA and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res treat 1995 ; 36 : 41-8
22. 22 O'Dwyer PJ, O'Sullivan F, Mc Dermott E, Losty P, O'Higgins NJ. CEA and CA 15-3 in primary and recurrent breast cancer. World J Surg 1990; 14 : 562-5
23. 23 O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 1995 ; 71 : 1288-91
24. 24 Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D et al. Clinical value of CA15.3, MCA, TPA and CEA in monitoring early breast cancers patients. Am J Clin Oncol 1996 ; 19 : 459-64
25. 25 Pirolo F, Pacini P, Borsotti M, La Morgia R, Mungai R, Cappellini M et al. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer. Anticancer Res 1991 ; 11 : 729-32
26. 26 Pons-Anicet DMF, Krebs BP, Mira R, Namer M. Value of CA 15-3 in the follow-up of breast cancer patients. Br J Cancer 1987 ; 55 : 567-9
27. 27 Repetto L, Onetto M, Gardin G, Costanzi B, Giudici S, Vitiello E et al. Serum CEA, CA 15-3 and MCA in breast cancer patients: a clinical evaluation. Cancer Detect and Prev 1993 ; 17 Suppl 3, 411-5
28. 28 Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989 ; 4 : 207-14
29. 29 Safi F, Kohler I, Rottinger E, Beger HG. The value of the tumour marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991 ; 68 : 574-82
30. 30 Scaramuzzi M, Amorotti C, De Palma M, Falchi AM, De Maria D, Casolo P. Prognostic significance of CA 13-3 in metastatic breast cancer. Int J Biol Markers 1990 ; 5 : 35-7
31. 31 Tobias R, Rothwell C, Wagner J, Green A, Liu YSV. Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast cancer tumor associated antigen 115D8/DF3. Proceedings of the Symposium of the American Association for Analytical. Clinical Chemistry, 1985; Atlanta
32. 32 Tomin R, Donegan WL. Screening for recurrent breast cancer - its effectiveness and prognostic value. J Clin Oncol 1987 ; 5 : 62-7
33. 33 Vizcarra E, Lluch A, Cibrian R, Jarque F, Alberola V, Belloch V et al. Value of CA15.3 in breast cancer and comparison with CEA ant TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 1996 : 37 : 209-16
34. 34 Wojtacki J, Dziewulska-Bokiniec A, Skokowski J, Ciesielski D. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study. Neoplasma 1994 ; 41 : 213-16